Summary: VICE reports on the ongoing discussion about ethics regarding patent applications of psychedelic substances and psychedelic-assisted therapy, which are on the rise amidst “the explosion of for-profit psychedelic companies.” Rick Doblin, Ph.D., and Ismail L. Ali, J.D., of MAPS both provide arguments against the use of patents in the psychedelic space.
“The fact that organizations like MAPS and Usona [Institute] exist, both of which are quite successful, and are well on their way to commercializing these drug products within kind of the mainstream medical system, does show that there’s at least some other way,” says Ali. “I’m not saying that MAPS is the perfect way or Usona is the perfect way, but there’s another way.”
Originally appearing here.
